Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: An approach involving peptide transporter-mediated influx across rabbit cornea

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 2, 2006, Pages 110-120

  Katragadda, Suresh ^a   Talluri, Ravi S ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; CARBON 14; CARRIER PROTEIN; ERYTHROMYCIN; GLYCOPROTEIN P; GLYCYLSARCOSINE; PRODRUG; QUINIDINE; RITONAVIR; UNCLASSIFIED DRUG; VALYLQUINIDINE; VALYLVALYLQUINIDINE; VERAPAMIL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORNEA; DERIVATIZATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG UPTAKE; MALE; MEMBRANE PERMEABILITY; NONHUMAN; RABBIT; TISSUE HOMOGENATE;

ANIMALS; CORNEA; EPITHELIAL CELLS; MALE; MEMBRANE TRANSPORT PROTEINS; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; PERMEABILITY; PRODRUGS; QUINIDINE; RABBITS; SUBSTRATE SPECIFICITY;

EID: 33646707458     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.110     Document Type: Article

References (40)

1. Shtil, A.A., Grinchuk, T.M., Tee, L., et al. Overexpression of P-glycoprotein is associated with a decreased mitochondrial transmembrane potential in doxorubicin-selected K562 human leukemia cells. Int. J. Oncol. 17:387-392, 2000.
2. Ueda, K., Okamura, N., Hirai, M., et al. Human P-glycoprotein transports cortisol, aldosterone, and dex-amethasone, but not progesterone. J. Biol. Chem. 267:24248-24252, 1992.
3. Perloff, M.D., Von Moltke, L.L., Marchand, J.E., et al. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci. 90:1829-1837, 2001.
4. Huisman, M.T., Smit, J.W., Wiltshire, H.R., et al. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J. Pharmacol. Exp. Ther. 304:596-602, 2003.
5. Duvvuri, S., Gandhi, M.D., and Mitra, A.K. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr. Eye Res. 27:345-353, 2003.
6. Holash, J.A., and Stewart, P.A. The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers. Brain Res. 629:218-224, 1993.
7. Kennedy, B.G., and Mangini, N.J. P-glycoprotein expression in human retinal pigment epithelium. Mol. Vis. 8:422-430, 2002.
8. Wu, J., Zhang, J.J., Koppel, H., et al. P-glycoprotein regulates a volume-activated chloride current in bovine nonpigmented ciliary epithelial cells. J. Physiol. 491(Pt 3):743-755, 1996.
9. Saha, P., Yang, J.J., and Lee, V.H. Existence of a P-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells. Invest. Ophthalmol. Vis. Sci. 39:1221-1226, 1998.
10. Dey, S., Patel, J., Anand, B.S., et al. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Vis. Sci. 44:2909-2918, 2003.
11. Kupferman, A., and Leibowitz, H.M. Topically applied steroids in corneal disease. IV. The role of drug concentration in stromal absorption of prednisolone acetate. Arch. Ophthalmol. 91:377-380, 1974.
12. Huang, H.S., Schoenwald, R.D., and Lach, J.L. Corneal penetration behavior of beta-blocking agents III: In vitro-in vivo correlations. J. Pharm. Sci. 72:1279-1281, 1983.
13. Baum, J., and Barza, M. Topical versus subconjunctival treatment of bacterial corneal ulcers. Ophthalmology 90:162-168, 1983.
14. Agata, M., Tanaka, M., Nakajima, A., et al. [Ocular penetration of topical diclofenac sodium, a nonsteroidal anti-inflammatory drug, in rabbit eye]. Nippon Ganka Gakkai Zasshi 88:991-996, 1984.
15. Dey, S., Gunda, S., and Mitra, A.K. Pharmacokinetics of erythromycin in rabbit corneas after single-dose in-fusion: Role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J. Pharmacol. Exp. Ther. 311:246-255, 2004.
16. D'Emanuele, A., Jevprasesphant, R., Penny, J., et al. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control Release 95:447-453, 2004.
17. Guillemard, V., and Uri Saragovi, H. Prodrug chemotherapeutics bypass P-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 23:3613-3621, 2004.
18. Killian, D.M., and Chikhale, P.J. A bioreversible prodrug approach designed to shift mechanism of brain uptake for amino-acid-containing anticancer agents. J. Neurochem. 76:966-974, 2001.
19. Sadzuka, Y., Yamashita, Y., Kishimoto, S., et al. [Glutamate transporter-mediated increase of antitumor activity by theanine, an amino acid in green tea]. Yakugaku Zasshi 122:995-999, 2002.
20. Bildin, V.N., Iserovich, P., Fischbarg, J., et al. Differential expression of Na:K:2Cl cotransporter, glucose transporter 1, and aquaporin 1 in freshly isolated and cultured bovine corneal tissues. Exp. Biol. Med. (Maywood) 226:919-926, 2001.
21. Anand, B.S., and Mitra, A.K. Mechanism of corneal permeation of L-valyl ester of acyclovir: Targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res. 19:1194-1202, 2002.
22. Jain-Vakkalagadda, B., Dey, S., Pal, D., et al. Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest. Ophthalmol. Vis. Sci. 44:2919-2927, 2003.
23. Jain-Vakkalagadda, B., Pal, D., Gunda, S., et al. Identification of a Na+-dependent cationic and neutral amino acid transporter, B0, +, in human and rabbit cornea. Mol. Pharm. 1:338-346, 2004.
24. Chidlow, G., Wood, J.P., Graham, M., et al. Expression of monocarboxylate transporters in rat ocular tissues. Am. J. Physiol. Cell. Physiol. 288:C416-428, 2005.
25. Majumdar, S., Gunda, S., and Mitra, A. Functional expression of a sodium-dependent nucleoside transporter on rabbit cornea: Role in corneal permeation of acyclovir and idoxuridine. Curr. Eye Res. 26:175-183, 2003.
26. Dantzig, A.H., and Bergin, L. Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim. Biophys. Acta. 1027:211-217, 1990.
27. Han, H., de Vrueh, R.L., Rhie, J.K., et al. 5′-amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 15:1154-1159, 1998.
28. Anand, B., Nashed, Y., and Mitra, A. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity, and transport across rabbit cornea. Curr. Eye Res. 26:151-163, 2003.
29. Anand, B.S., Hill, J.M., Dey, S., et al. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest. Ophthalmol. Vis. Sci. 44:2529-2534, 2003.
30. Rice, A., Michaelis, M.L., Georg, G., et al. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J. Mol. Neurosci. 20:339-343, 2003.
31. Rouquayrol, M., Gaucher, B., Roche, D., et al. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. Pharm. Res. 19:1704-1712, 2002.
32. Rousselle, C., Clair, P., Lefauconnier, J.M., et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57:679-686, 2000.
33. Jain, R., Majumdar, S., Nashed, Y., et al. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol. Pharm. 1:290-299, 2004.
34. Tak, R.V., Pal, D., Gao, H., et al. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. J. Pharm. Sci. 90:1505-1515, 2001.
35. Cheng, Y., and Prusoff, W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor, which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108, 1973.
36. Anthonypillai, C., Sanderson, R.N., Gibbs, J.E., et al. The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J. Pharmacol. Exp. Ther. 308:912-920, 2004.
37. Babu, E., Kanai, Y., Chairoungdua, A., et al. Identification of a novel system L-amino acid transporter structurally distinct from heterodimeric amino acid transporters. J. Biol. Chem. 278:43838-43845, 2003.
38. Sugawara, M., Huang, W., Fei, Y.J., et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89:781-789, 2000.
39. Balimane, P.V., Tamai, I., Guo, A., et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 250:246-251, 1998.
40. Balimane, P., and Sinko, P. Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm. Drug Dispos. 21:165-174, 2000.